Health Care › Biological Products (No Diagnostic Substances)
LCTX Stock Price Correlated With Lineage Cell Therapeutics Financials
External Links ⌄
Income Statement
Cash Flow
Balance Sheet
LCTX Income Statement
Enable JavaScript and reload
Revenue, Net:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
LCTX Cash Flow
Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:
LCTX Balance Sheet
Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:
COMPANY PROFILE
1.
Organization, Basis of Presentation and Liquidity
Lineage Cell Therapeutics,
Inc. (“Lineage,” “we,” “us,” or “our”) is a clinical-stage biotechnology company developing
novel cell therapies to address unmet medical needs. Our programs are based on our proprietary cell-based technology and associated development
and manufacturing capabilities. From this platform, we design, develop, and manufacture specialized human cells with anatomical and physiological
functions which are similar or identical to cells found naturally in the human body. These cells which we manufacture are created by
developmental differentiation protocols applied to established and well-characterized, pluripotent, and self-renewing cell lines. These
functional cells are transplanted into patients to either replace or support cells that are dysfunctional or absent due to degenerative
disease or traumatic injury, or are administered as a means of helping the body mount a more robust and effective immune response to
cancer or infectious diseases.
Our
strategy is to efficiently leverage our technology platform and manufacturing capabilities to develop and advance our programs internally
or in conjunction with strategic partners to further enhance their value. As one example, on December 17, 2021, we entered into a Collaboration
and License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc., a member of the Roche Group (collectively, “Roche”),
wherein Lineage granted to Roche exclusive worldwide rights to develop and commercialize retinal pigment epithelium cell therapies, including its proprietary cell therapy known as OpRegen®, for the treatment of ocular disorders, including advanced
dry age-related macular degeneration with geographic atrophy. Roche has paid Lineage a $ 50.0 million upfront payment under this alliance
and Lineage is eligible to receive up to an additional $ 620.0 million in certain developmental, regulatory, and commercialization milestone
payments. Lineage also is eligible for tiered double-digit percentage royalties on net sales of OpRegen.
Currently,
Lineage is working with Roche in support of the dry age-related macular degeneration (OpRegen) program and is clinically testing
therapies to treat spinal cord injuries and non-small cell lung cancer, as well as conducting research and preclinical development activities
intended to advance our pipeline into other therapeutic indications and target tissues or organs.
Product
Candidates & Other Programs
We
have several allogeneic, or “off-the-shelf,” cell therapy programs in development:
●
OpRegen ®,
a retinal pigment epithelium (“RPE”) cell replacement therapy currently in a Phase 1/2a multicenter clinical trial for
the treatment of advanced dry age-related macular degeneration (“AMD”) with geographic atrophy (“GA”) (also
known as atrophic AMD). There are currently no therapies approved by the U.S. Food and Drug Administration (“FDA”) for
dry AMD. As of December 17, 2021 this program has been partnered with Roche for further clinical development and commercialization.
●
OPC1,
an oligodendrocyte progenitor cell therapy currently in long-term follow-up for a Phase 1/2a multicenter clinical trial for spinal
cord injuries (“SCI”). This clinical trial has been partially funded by the California Institute for Regenerative Medicine
(“CIRM”).
●
VAC,
an allogeneic cancer immunotherapy of antigen-presenting dendritic cells. One of the VAC product candidates, VAC2, is currently in
a Phase 1 clinical trial in non-small cell lung cancer (“NSCLC”). This clinical trial is being funded and conducted by
Cancer Research UK, one of the world’s largest independent cancer research charities. We also have another VAC-based product
candidate in preclinical development with our partner, Immunomic Therapeutics, Inc. (“ITI”), for the treatment of glioblastoma
multiforme (“GBM”).
●
Other.
We have other product candidates
in preclinical development c
Organization, Basis of Presentation and Liquidity
Lineage Cell Therapeutics,
Inc. (“Lineage,” “we,” “us,” or “our”) is a clinical-stage biotechnology company developing
novel cell therapies to address unmet medical needs. Our programs are based on our proprietary cell-based technology and associated development
and manufacturing capabilities. From this platform, we design, develop, and manufacture specialized human cells with anatomical and physiological
functions which are similar or identical to cells found naturally in the human body. These cells which we manufacture are created by
developmental differentiation protocols applied to established and well-characterized, pluripotent, and self-renewing cell lines. These
functional cells are transplanted into patients to either replace or support cells that are dysfunctional or absent due to degenerative
disease or traumatic injury, or are administered as a means of helping the body mount a more robust and effective immune response to
cancer or infectious diseases.
Our
strategy is to efficiently leverage our technology platform and manufacturing capabilities to develop and advance our programs internally
or in conjunction with strategic partners to further enhance their value. As one example, on December 17, 2021, we entered into a Collaboration
and License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc., a member of the Roche Group (collectively, “Roche”),
wherein Lineage granted to Roche exclusive worldwide rights to develop and commercialize retinal pigment epithelium cell therapies, including its proprietary cell therapy known as OpRegen®, for the treatment of ocular disorders, including advanced
dry age-related macular degeneration with geographic atrophy. Roche has paid Lineage a $ 50.0 million upfront payment under this alliance
and Lineage is eligible to receive up to an additional $ 620.0 million in certain developmental, regulatory, and commercialization milestone
payments. Lineage also is eligible for tiered double-digit percentage royalties on net sales of OpRegen.
Currently,
Lineage is working with Roche in support of the dry age-related macular degeneration (OpRegen) program and is clinically testing
therapies to treat spinal cord injuries and non-small cell lung cancer, as well as conducting research and preclinical development activities
intended to advance our pipeline into other therapeutic indications and target tissues or organs.
Product
Candidates & Other Programs
We
have several allogeneic, or “off-the-shelf,” cell therapy programs in development:
●
OpRegen ®,
a retinal pigment epithelium (“RPE”) cell replacement therapy currently in a Phase 1/2a multicenter clinical trial for
the treatment of advanced dry age-related macular degeneration (“AMD”) with geographic atrophy (“GA”) (also
known as atrophic AMD). There are currently no therapies approved by the U.S. Food and Drug Administration (“FDA”) for
dry AMD. As of December 17, 2021 this program has been partnered with Roche for further clinical development and commercialization.
●
OPC1,
an oligodendrocyte progenitor cell therapy currently in long-term follow-up for a Phase 1/2a multicenter clinical trial for spinal
cord injuries (“SCI”). This clinical trial has been partially funded by the California Institute for Regenerative Medicine
(“CIRM”).
●
VAC,
an allogeneic cancer immunotherapy of antigen-presenting dendritic cells. One of the VAC product candidates, VAC2, is currently in
a Phase 1 clinical trial in non-small cell lung cancer (“NSCLC”). This clinical trial is being funded and conducted by
Cancer Research UK, one of the world’s largest independent cancer research charities. We also have another VAC-based product
candidate in preclinical development with our partner, Immunomic Therapeutics, Inc. (“ITI”), for the treatment of glioblastoma
multiforme (“GBM”).
●
Other.
We have other product candidates
in preclinical development c
Free historical financial statements for Lineage Cell Therapeutics, Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 51 quarters since 2012. Compare with LCTX stock chart to see long term trends.
Data imported from Lineage Cell Therapeutics, Inc. SEC filings. Check original filings before making any investment decision.